Page 4 - Abakkus Growth Fund News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Abakkus growth fund. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Abakkus Growth Fund Today - Breaking & Trending Today

AGS Transact IPO in progress: Should you subscribe to the issue?

The firm has fixed a price band of Rs 166-175 for the first IPO of 2022. The issue will close on January 21. ....

Anand Rathi , Ravib Goyal , Saint Capital Fund , Abakkus Growth Fund , Vineha Enterprises , Mutual Fund , Ashoka India Equity Investment Trust Plc , Opportunities Fund , Kuber India Fund , India Equity Investment Trust Plc , Nippon India , Welfare Trust , Aadhaar Enabled Payment System , Subscribe Long Term , Ags Transact Technologies Ipo , Gs Transact Technologies Ipo Lot Size , Gs Transact Technologies Ipo Price Band , Gs Transact Technologies Ipo Issue Size , Gs Transact Technologies Ipo Closing Date ,

AGS Transact IPO: Retail quota fully subscribed on day one, check latest GMP, expected listing price

AGS Transact IPO: Retail quota fully subscribed on day one, check latest GMP, expected listing price
india.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from india.com Daily Mail and Mail on Sunday newspapers.

New Delhi , Ravib Goyal , Saint Capital Fund , Abakkus Growth Fund , Mutual Fund , Indian Renewable Energy Development Agency Ltd , Ashoka India Equity Investment Trust Plc , Opportunities Fund , Kuber India Fund , India Equity Investment Trust Plc , Nippon India , Also Read , Indian Renewable Energy Development Agency ,

IPO Update: Shyam Metalics IPO subscribed 2.04 times on Day 2

IPO Update: Shyam Metalics IPO subscribed 2.04 times on Day 2
businesstoday.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesstoday.in Daily Mail and Mail on Sunday newspapers.

United Kingdom , Shyam Metalics , Asia Opportunities Fund , Abakkus Growth Fund , Power Ltd , Insurance Company , Aditya Birla Sun Life Insurance Company , Aurgin Master Fund Ltd , Energy Ltd , Marwadi Financial Services , Kotak Mutual Fund , Tata Steel , Kotak Offshore , Opportunities Fund , Offer For Sale , Marwadi Financial , ஒன்றுபட்டது கிஂக்டம் , ஆசியா வாய்ப்புகள் நிதி , பவர் லிமிடெட் , காப்பீடு நிறுவனம் , ஆற்றல் லிமிடெட் , மார்வாடி நிதி சேவைகள் , கோட்டக் பரஸ்பர நிதி , டாடா எஃகு , வாய்ப்புகள் நிதி , சலுகை க்கு விற்பனை ,

Shyam Metalics IPO opens June 14: Should you subscribe to the issue?

The company has allocated 88,21,764 equity shares to 21 anchor investors at a price of Rs 306 per equity share. ....

United Kingdom , Shyam Metalics , Asia Opportunities Fund , Abakkus Growth Fund , Power Ltd , Insurance Company , Aditya Birla Sun Life Insurance Company , Aurgin Master Fund Ltd , Energy Ltd , Marwadi Financial Services , Kotak Mutual Fund , Tata Steel , Kotak Offshore , Opportunities Fund , Offer For Sale , Marwadi Financial , Shyam Metalics And Energy Ltd , Anchor Investors , ஒன்றுபட்டது கிஂக்டம் , ஆசியா வாய்ப்புகள் நிதி , பவர் லிமிடெட் , காப்பீடு நிறுவனம் , ஆற்றல் லிமிடெட் , மார்வாடி நிதி சேவைகள் , கோட்டக் பரஸ்பர நிதி , டாடா எஃகு ,

SPARC announces positive top-line results for ophthalmic drug

Sun Pharma Advanced Research Company (SPARC) announced positive top-line results from pivotal phase 3 clinical trial of PDP-716 for the treatment of ocular hypertension.
SPARC reported positive top-line results from its Phase 3 trial (CLR 16 33) for its investigational drug, PDP-716 ophthalmic suspension, for the treatment of open angle glaucoma or ocular hypertension.
PDP-716 is a novel, once daily, ophthalmic suspension of Brimonidine Tartrate 0.35%. PDP-716 is developed using SPARC s proprietary TearAct technology.
The trial met its pre-specified primary endpoint, demonstrating that PDP-716 dosed once daily is equivalent to Alphagan P 0.1% dosed 3 times a day.
We are very pleased by these results for PDP-716. Once daily dosing of PDP-716 can significantly reduce the dosing frequency compared to currently marketed formulation and can have positive impact on quality of life for patients with Glaucoma. said Anil Raghavan, CEO of SPARC. ....

Dilip Shantilal Shanghvi , Aashish Maheshwari , Rekha Jhunjhunwala , Abakkus Growth Fund , University Of Notre Dame Du Lac , Sun Pharma Advanced Research Company , Brimonidine Tartrate , Sanil Raghavan , Authum Investment , Notre Dame , Cohesion Investment , Capital Market , Bse Sensex , Nifty 50 , Sun Pharma , Pharmaceutical Companies , Kite Pharma , Biotechnology Amp Medical Research Nec , Sanil Raghavan , Brimonidine Tartrate , Sun Pharma Advanced Research Company , Rekha Jhunjhunwala , University Of , நீர்த்துப்போக சாந்திலால் ஷாங்க்வி , ஆஷிஷ் மகேஸ்வரி , ரேகா ஜுன்ஜுன்வாலா ,